Novonesis (Novozymes) B (NSISBC.XD)
DKK 410.0
(-0.89%)
DKK 410.0
(-0.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.97 Billion DKK | -11.27% |
| 2022 | 4.48 Billion DKK | 15.07% |
| 2021 | 3.89 Billion DKK | 6.31% |
| 2020 | 3.66 Billion DKK | 2.09% |
| 2019 | 3.58 Billion DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 503.51 Million DKK | -47.28% |
| 2024 Q2 | 503.48 Million DKK | -0.01% |
| 2023 Q2 | 1.01 Billion DKK | -15.75% |
| 2023 Q4 | 955 Million DKK | -19.34% |
| 2023 Q1 | 1.2 Billion DKK | 31.72% |
| 2023 FY | 4.46 Billion DKK | -0.4% |
| 2023 Q3 | 1.18 Billion DKK | 17.11% |
| 2022 Q3 | 1.31 Billion DKK | 0.0% |
| 2022 FY | 4.48 Billion DKK | 15.07% |
| 2022 Q4 | 911 Million DKK | -30.88% |
| 2021 FY | 3.89 Billion DKK | 6.31% |
| 2020 FY | 3.66 Billion DKK | 2.09% |
| 2019 FY | 3.58 Billion DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|